HAIM
UNCY icon

Hunter Associates Investment Management’s Unicycive Therapeutics UNCY Stock Holding History

Hunter Associates Investment Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,500
Closed -$12K – 264
2024
Q4 		$12K Buy
+1,500
New +$8.3K ﹤0.01% 254

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hunter Associates Investment Management's UNCY Position: Q1 2025 in Review

Hunter Associates Investment Management sold out of Unicycive Therapeutics (UNCY) in Q1 2025, closing a stake of 1,500 shares — an estimated $12K sold.

Hunter Associates Investment Management first reported a position in UNCY in Q4 2024 and held it in 1 quarter. The position peaked at $12K in Q4 2024. 29 funds tracked by Wall St. Rank hold UNCY as of Q1 2025.

  • Hunter Associates Investment Management reported no remaining Unicycive Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Hunter Associates Investment Management sold 1,500 Unicycive Therapeutics shares in Q1 2025, an estimated $12K.
  • Hunter Associates Investment Management first reported a position in Unicycive Therapeutics in Q4 2024 and held it in 1 quarter.
  • Hunter Associates Investment Management's Unicycive Therapeutics position peaked at $12K in Q4 2024.
  • 29 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2025.

Based on Hunter Associates Investment Management's 13F filing for Q1 2025, filed 30 Apr 2025.